.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Dow
Federal Trade Commission
Citi
Express Scripts
Deloitte
Healthtrust
Colorcon
Queensland Health
Mallinckrodt

Generated: December 13, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,599,498

« Back to Dashboard

Which drugs does patent 6,599,498 protect, and when does it expire?


Patent 6,599,498 protects FERAHEME and is included in one NDA. There has been one Paragraph IV challenge on Feraheme.

This patent has eleven patent family members in ten countries.

Summary for Patent: 6,599,498

Title: Heat stable colloidal iron oxides coated with reduced carbohydrates and carbohdrate derivatives
Abstract:Compositions, methods of making the compositions, and methods of using the compositions are provided for an enhanced magnetic resonance imaging agent and a hematinic agent, the agents comprising carboxyalkylated reduced polysaccharides coated ultrasmall superparamagnetic iron oxides. Methods of use of the carboxymethyl reduced dextran as a plasma extender are provided.
Inventor(s): Groman; Ernest V. (Brookline, MA), Paul; Kenneth G. (Holliston, MA), Frigo; Timothy B. (Waltham, MA), Bengele; Howard (Canton, MA), Lewis; Jerome M. (Newton, MA)
Assignee: Advanced Magnetics, Inc. (Cambridge, MA)
Application Number:09/521,264
Patent Claim Types:
see list of patent claims
Use; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Amag Pharms IncFERAHEMEferumoxytolSOLUTION;INTRAVENOUS022180-001Jun 30, 2009RXYesYes► Subscribe► Subscribe► SubscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,599,498

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,553,479Heat stable colloidal iron oxides coated with reduced carbohydrates and uses thereof► Subscribe
9,555,133Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents► Subscribe
8,591,864Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents► Subscribe
8,926,947Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents► Subscribe
8,501,158Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents► Subscribe
7,871,597Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,599,498

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Denmark1169062► Subscribe
Japan5064612► Subscribe
European Patent Office1169062► SubscribeC300558Netherlands► Subscribe
European Patent Office1169062► SubscribeCA 2012 00050Denmark► Subscribe
European Patent Office1169062► Subscribe92114Luxembourg► Subscribe
European Patent Office1169062► SubscribeC01169062/01Switzerland► Subscribe
European Patent Office1169062► Subscribe1290043-7Sweden► Subscribe
European Patent Office1169062► Subscribe300558Netherlands► Subscribe
Luxembourg92114► Subscribe
European Patent Office1522318► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Cerilliant
Medtronic
Harvard Business School
US Department of Justice
Covington
Novartis
Accenture
Daiichi Sankyo
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot